-
Mashup Score: 2Semaglutide Eligibility Expands to Over Half of US Adults - 6 month(s) ago
Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Source: www.ajmc.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 10Analysis finds no increased risk of mental health issues among those using semaglutide for weight loss - 8 month(s) ago
Taking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according …
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet-
Analysis finds no increased risk of mental health issues among those using #semaglutide for weight loss @pennmedicine @JAMAInternalMed https://t.co/JQzxVsT62X
-
-
Mashup Score: 3Prescription-Free Online Semaglutide Is Risky Business - 9 month(s) ago
Over 40% of pharmacy sites offering GLP-1 drug without a script are known to operate illegally
Source: www.medpagetoday.comCategories: General Medicine News, General HCPsTweet-
A qualitative study of #semaglutide (Ozempic, Wegovy) purchases over the internet without a prescription uncovered scams, low purity levels, and possible contamination of products. https://t.co/UxUOAVNvio
-
-
Mashup Score: 10Wegovy: GP pilot scheme could be scrapped after failing to launch - 9 month(s) ago
The pilot scheme for making the weight loss drug semaglutide (marketed as Wegovy) more widely available, announced last June by then prime minister Rishi Sunak, could be scrapped, as the new government reviews how to roll out obesity treatment across England. The two year pilot scheme, backed with £40m in funding, aimed to improve access to semaglutide in the community, by expanding specialist weight management services outside hospitals, including through GPs.1 However, despite promises that the pilots would launch in late 2023 or early 2024, The BMJ understands that …
Source: www.bmj.comCategories: General Medicine News, General Journals & SocietTweet-
The pilot scheme for making the weight loss drug #semaglutide (Wegovy) more widely available could be scrapped, as the new government reviews how to roll out obesity treatment across England https://t.co/X1x49jVLFD
-
-
Mashup Score: 15
The US Food and Drug Administration (FDA) has published a warning to the public and healthcare providers after receiving reports that patients are overdosing on semaglutide, with some requiring hospital admission.1 FDA said the overdose reports it has received were related to “dosing errors involving compounded semaglutide injectable products dispensed in multiple dose vials.” It warned that in some instances, patients …
Source: www.bmj.comCategories: General Medicine News, General HCPsTweet-
The US Food and Drug Administration has published a warning to the public and healthcare providers after receiving reports that patients are overdosing on #semaglutide https://t.co/xsdWAPh0Pg
-
-
Mashup Score: 15
The US Food and Drug Administration (FDA) has published a warning to the public and healthcare providers after receiving reports that patients are overdosing on semaglutide, with some requiring hospital admission.1 FDA said the overdose reports it has received were related to “dosing errors involving compounded semaglutide injectable products dispensed in multiple dose vials.” It warned that in some instances, patients …
Source: www.bmj.comCategories: General Medicine News, General HCPsTweet-
The US Food and Drug Administration has published a warning to the public and healthcare providers after receiving reports that patients are overdosing on #semaglutide https://t.co/xsdWAPh0Pg
-
-
Mashup Score: 4Possible Connection Between Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy - 9 month(s) ago
Nonarteritic anterior ischemic optic neuropathy (NAION) is uncommon, but it can cause blindness. The etiology is unknown, but NAION has been associated
Source: www.jwatch.orgCategories: General Medicine News, General HCPsTweet-
An observational study noted a possible connection between #semaglutide and nonarteritic anterior ischemic optic neuropathy. https://t.co/qdhyiNWpUJ https://t.co/o9rpezgbMR
-
-
Mashup Score: 3
The FDA is warning providers and patients that dosing errors with compounded injectable semaglutide may be leading to adverse events, according to a press release.The FDA has received reports of adverse events, some of which led to hospitalization, that may be tied to overdosing with compounded semaglutide. The agency stated the overdosing may be due to a lack of experience with self-injections
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
🚨Overdosing with compounded #semaglutide may be leading to adverse events and hospitalization for some patients, according to the @US_FDA. Read more ⬇️ @GoHealio https://t.co/v9bBmaJLbh
-
-
Mashup Score: 20
Doctors in the UK will be able to prescribe the weight loss drug semaglutide (Wegovy) to reduce the risk of serious heart problems or strokes in overweight and obese people, after the Medicines and Healthcare Products Regulatory Agency (MHRA) approved a new indication for the drug. The GLP-1 receptor agonist is already approved on the NHS for treating obesity—a body mass index (BMI) of 35 or more—and for weight management in people with a BMI of 30.0-34.9 who meet criteria for referral to specialist weight management services. It is manufactured by Novo Nordisk and administered by injection in a prefilled pen. The new approval will …
Source: www.bmj.comCategories: General Medicine News, General HCPsTweet-
Doctors in the UK will be able to prescribe #semaglutide to reduce the risk of serious heart problems or strokes in overweight and obese people, after the UK regulator approved a new indication for the drug https://t.co/cSDDP7iueG
-
-
Mashup Score: 90
On 10 October 2023, Novo Nordisk1 announced the decision to stop the kidney outcome trial FLOW (Effect of semaglutide versus placebo on the progression of renal
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet-
FLOW trial stopped early due to evidence of renal protection with #semaglutide https://t.co/ClX7IqnimD
-
Over half of the US adult population may benefit from #semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications: https://t.co/u1DasNwbU8 https://t.co/7MWTkymqI4